Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Scand J Rheumatol ; 50(1): 52-57, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32865088

RESUMEN

Objective: Subglottic stenosis (SGS) is a severe, life-threatening disease found in immune-mediated diseases such as granulomatosis with polyangiitis (GPA) and in rare cases of immunoglobulin G4 (IgG4)-related disease. It can result in persistent airway compromise due to the fibrotic response following inflammation. Standard management involves repeated endoscopic interventions to dilate the airway, and tracheostomy is occasionally required. In addition, immunosuppression remains a cornerstone of therapy aimed at controlling the underlying inflammatory disease; however, cumulative dosing leads to significant adverse effects. We present five cases of predominantly anti-neutrophil cytoplasmic antibody-negative GPA and a case of IgG4-related disease with SGS, in whom we evaluated the long-term utility of sirolimus, which has beneficial anti-proliferative and fibrotic effects, in the management of their disease. Method: We conducted a retrospective review of a cohort of patients with SGS at a tertiary vasculitis unit. These patients were treated with sirolimus, in addition to conventional medical and endoscopic treatment. Clinical symptoms, frequency and time to endoscopic intervention pre- and post-treatment, additional rescue therapy, and any adverse effects were recorded and analysed. Results: Six patients were treated with sirolimus and followed for up to 9 years; two discontinued the drug owing to adverse effects, early on. In the remaining four patients, glucocorticoids were withdrawn, and the frequency of endoscopic intervention was reduced. One patient on sirolimus required rituximab therapy for disease flare. Conclusion: Sirolimus may be a therapeutic option for some patients with severe SGS, allowing steroid withdrawal and resulting in a positive adverse effect profile.


Asunto(s)
Antibióticos Antineoplásicos/uso terapéutico , Granulomatosis con Poliangitis/complicaciones , Enfermedad Relacionada con Inmunoglobulina G4/complicaciones , Laringoestenosis/tratamiento farmacológico , Sirolimus/uso terapéutico , Adulto , Femenino , Humanos , Laringoestenosis/inmunología , Masculino , Estudios Retrospectivos , Resultado del Tratamiento
2.
Ann Rheum Dis ; 70(12): 2229-33, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21859691

RESUMEN

OBJECTIVES: To determine a role for antineutrophil cytoplasmic antibody (ANCA)-activated neutrophils in promoting B cell survival through the release of B lymphocyte stimulator (BLyS). METHODS: Neutrophil BLyS expression was measured by flow cytometry. Concentrations of BLyS in cell supernatants and donor serum samples were measured by ELISA. Cell survival assays were carried out using an L3055 cell line and viability measured by flow cytometry. RESULTS: Tumour necrosis factor α and formyl-Met-Leu-Phe (fMLP) treatment of non-primed neutrophils and treatment of primed neutrophils with anti-PR3 ANCA IgG resulted in a significant increase in surface expression of BLyS within 30 min which returned to basal levels by 2 h. Supernatants from ANCA-stimulated neutrophils were shown to contain increased levels of BLyS and to promote the survival of the centroblast cell line L3055. Serum BLyS concentrations are increased in patients with active ANCA-associated systemic vasculitis and these levels are increased further following 1-3 months of treatment with rituximab. CONCLUSIONS: ANCA specifically causes the release of BLyS from activated neutrophils which can support B cell survival in vitro. The presence of serum BLyS in active disease and its increase following B cell depletion suggest it is an important factor in disease pathogenesis and may facilitate disease relapse.


Asunto(s)
Anticuerpos Anticitoplasma de Neutrófilos/inmunología , Factor Activador de Células B/sangre , Linfocitos B/inmunología , Neutrófilos/inmunología , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Supervivencia Celular/inmunología , Femenino , Humanos , Inmunoglobulina G/sangre , Factores Inmunológicos/uso terapéutico , Masculino , Persona de Mediana Edad , Rituximab , Vasculitis Sistémica/tratamiento farmacológico , Vasculitis Sistémica/inmunología , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA